Research Article| Volume 196, P6-10, January 2016

Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial

Published:October 15, 2015DOI:


      Introduction and hypothesis

      The aim of this study was to evaluate the effectiveness of transcutaneous posterior tibial nerve stimulation (T.C. PTNS) versus extended release oxybutynin (E.R.O.) in patients with overactive bladder.

      Materials and methods

      Seventy female patients were randomized to receive either 10 mg E.R.O. daily or T.C. PTNS, using a TENS machine program with the 20 Hz, 200 cycles/s, and normal stimulation setting for two 30-min sessions, each week for a 12-week period. Pre-treatment and after the 12-week intervention, each patient completed a 3-day voiding diary and a self-report quality of life questionnaire (OAB-q). Statistical analysis was performed using Stata V12.1.


      Sixty-four patients completed the treatment protocol. There were no significant differences between study groups in terms of age, body mass index, past hormone replacement therapy, smoking habits, menopause status, and parity. Prior to treatment, there were also no significant differences in the analysis of the 3-day voiding diary or in the OAB-q questionnaire results. Following the 12-week study, there was a statistically significant reduction in frequency of urination, urgency episodes, and urge incontinent episodes compared to pre-treatment values. However, there were no significant differences in these values between intervention groups after 12-weeks of therapy. There was a similar improvement in OAB-q scores in both treatment groups following therapy, and the T.C. PTNS group showed a statistically significant improvement over the E.R.O. in domain 2 of the OAB-q questionnaire. The other two domains showed similar improvement in both study groups.


      T.C. PTNS and E.R.O. demonstrated similar improvements in subjects with OAB in a 12-week study.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Halen B.T.
        • de Ridder D.
        • Freeman R.
        • Swift S.
        • Berghmans B.
        • Lee J.
        An International Urogynecology Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
        Neurourol Urodyn. 2010; 29: 4-20
        • Irwin D.E.
        • Milsom I.
        • Hunskaar S.
        • et al.
        Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.
        Eur Urol. 2006; 50: 1306-1315
        • Stewart W.
        • Van Rooyen J.
        • Cundiff G.
        • et al.
        Prevalence and burden of overactive bladder in the United States.
        World J Urol. 2003; 20: 327-336
        • Gopal M.
        • Haynes K.
        • Bellamy S.L.
        • Arya L.A.
        Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms.
        Obstet Gynecol. 2008; 112: 1311-1318
        • Kay G.G.
        • Abou-Donia M.B.
        • Messer W.S.
        • Murphy D.G.
        • Tsao J.W.
        • Ouslander J.G.
        Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
        J Am Geriatr Soc. 2005; 53: 2195-2201
        • Vandoninck V.
        • van Balken M.R.
        • Agró E.F.
        • et al.
        Posterior tibial nerve stimulation in the treatment of urge incontinence.
        Neurourol Urodyn. 2003; 22: 17-23
        • Peters K.M.
        • MacDiarmid S.A.
        • Wooldridge L.S.
        • et al.
        Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
        J Urol. 2009; 182: 1055-1061
        • Ammi M.
        • Chautard D.
        • Brassart E.
        • Culty T.
        • Azzouzi A.R.
        • Bigot P.
        Transcutaneous posterior tibial nerve stimulation: evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder.
        Int Urogynecol J. 2014; 25: 1065-1069
        • Finazzi A.E.
        • Campagna A.
        • Sciobica F.
        • et al.
        Posterior tibial nerve stimulation: is the once-a-week protocol the best option?.
        Minerva Urol Nefrol. 2005; 57: 119-123
        • Van Der Pal F.
        • Van Balken M.R.
        • Heesakkers J.P.
        • Debruyne F.M.
        • Kiemeney L.A.
        • Bemelmans B.L.
        Correlation between quality of life and voiding variables in patients treated with percutaneous tibial nerve stimulation.
        BJU Int. 2006; 97: 113-116
        • Vandoninck V.
        • van Balken M.R.
        • Finazzi Agrò E.
        • et al.
        Posterior tibial nerve stimulation in the treatment of voiding dysfunction: urodynamic data.
        Neurourol Urodyn. 2004; 23: 246-251
        • Finazzi-Agrò E.
        • Rocchi C.
        • Pachatz C.
        • et al.
        Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials.
        Neurourol Urodyn. 2009; 28: 320-324
        • Nuhoğlu B.
        • Fidan V.
        • Ayyıldız A.
        • Ersoy E.
        • Germiyanoğlu C.
        Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up.
        Int Urogynecol J. 2006; 17: 204-207
        • Van Der Pal F.
        • Van Balken M.R.
        • Heesakkers J.P.
        • Debruyne F.M.
        • Bemelmans B.L.
        Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary?.
        BJU Int. 2006; 97: 547-550